Updated:
NRX Pharmaceuticals
We are NRx – a pioneering and focused CNS biopharma company, dedicated to meeting unmet medical needs for those with suicidal depression, suicidal bipolar...
NRX Pharmaceuticals
We are NRx – a pioneering and focused CNS biopharma company, dedicated to meeting unmet medical needs for those with suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). The company has filed an Abbreviated New Drug Application (ANDA) for NRX-100, preservative-free IV ketamine and has initiated filing of an NDA for NRX-100 in people with suicidal depression.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Radnor
Corporate office
Radnor, PA, United States
Principals
Jonathan Javitt
Chairman and Chief Scientist
Stephen Willard
Chief Executive Officer
Sector focus
Frequently asked questions
Who controls the clinical and regulatory strategy at NRX Pharmaceuticals?
Dr. Jonathan Javitt, the firm's founder, Chairman, and Chief Scientist, runs clinical and regulatory decisions. He has a public-health career spanning the White House Office of Science and Technology and prior biotech ventures including NeuroRx. CEO Stephen Willard oversees corporate operations and financing. Javitt's academic affiliation with Johns Hopkins informs the firm's clinical-trial design.
What is the firm's primary asset, and where does it stand with the FDA?
NRX-101, a fixed-dose oral combination of D-cycloserine and lurasidone, is the lead asset targeting suicidal bipolar depression. The FDA has granted it Qualified Infectious Disease Product and Fast Track designations. In July 2024, an independent monitoring board recommended its Phase 2b/3 trial proceed without changes, a signal the study did not require early termination for futility or safety.
How did NRX Pharmaceuticals access public markets?
NRX was formed through the May 2021 merger of NeuroRx, a private biotech, with Big Rock Partners Acquisition Corp., a publicly traded special purpose acquisition company. The SPAC deal gave the combined entity an equity valuation near $500 million and a Nasdaq listing under the ticker NRXP, typical of the 2020–2021 biotech listing wave.
Is NRX Pharmaceuticals a family office or a drug-development company?
It is a publicly traded clinical-stage pharmaceutical company, not a family office. The firm deploys its balance sheet — funded through equity raises — entirely toward advancing its own drug pipeline. It does not invest in external funds, co-invest alongside other allocators, or manage third-party capital.
Does NRX have any ownership stake in ketamine manufacturing or supply chain?
NRX does not own manufacturing assets. It has an exclusive supply-chain agreement with Nephron Pharmaceuticals for production of its ketamine-based formulations. The firm's intravenous ketamine, NRX-100, relies on this contract, while clinical supplies for NRX-101 are sourced through standard pharmaceutical manufacturing partnerships.
What happens if the Phase 2b/3 trial fails?
NRX is effectively a single-asset company. The failure of NRX-101 in its pivotal trial would likely force a restructuring, asset sale, or cessation of operations. The firm's pipeline beyond NRX-101 — a COVID-related asset and NRX-100 — remains early and unfunded for late-stage trials, making the lead program binary for the current corporate structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: